Economic evaluation of five first-line PD-(L)1 inhibitors for treating non-squamous non-small cell lung cancer in China: A cost-effectiveness analysis based on network meta-analysis.
Saved in:
| Title: | Economic evaluation of five first-line PD-(L)1 inhibitors for treating non-squamous non-small cell lung cancer in China: A cost-effectiveness analysis based on network meta-analysis. |
|---|---|
| Authors: | Chen X; Department of Pharmacoeconomics, School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.; Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, China., Zhao M; Department of Pharmacoeconomics, School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.; Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, China., Tian L; Department of Pharmacoeconomics, School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.; Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, China. |
| Source: | Frontiers in pharmacology [Front Pharmacol] 2023 Mar 20; Vol. 14, pp. 1119906. Date of Electronic Publication: 2023 Mar 20 (Print Publication: 2023). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1663-9812 |
|---|---|
| DOI: | 10.3389/fphar.2023.1119906 |
